Delivery Order SPE2DB22D3016-SPE2DB25FAMP3
Award Date
2/6/25
Potential Completion Date
2/28/25
Potential Value
$48K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $48,077.16, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract is a Firm Fixed Price Delivery Order with a period of performance ending on January 28, 2025. The contract was not set aside for any specific business category. In addition to this delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML. The contract has a ceiling value of $119,585.40 and a completion date of December 26, 2024. This is a firm fixed-price delivery order contract with no set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award, valued at $12,019.28, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication, with a period of performance through February 13, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $60,096.40 firm fixed-price delivery order contract is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has an ultimate completion date of February 18, 2025 and was awarded on January 27, 2025. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of OCREVUS 300 MG/10 ML vials. The contract has a ceiling value of $115,590.40 and runs through November 26, 2024. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999, which serves as a primary vehicle for providing a comprehensive range of...
This federal contract award, valued at $36,057.84, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. The contract has an ultimate completion date of February 18, 2025 and is a firm fixed-price arrangement. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC)...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $24,038.58, is a delivery order for the supply of OCREVUS 300 MG/1 ML 1S, a specialty medication. The contract is a firm fixed-price delivery order with a completion date of January 16, 2025. It is not associated with a set-aside program. AmerisourceBergen holds a significant...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, involves the delivery of OCREVUS 300 MG/10 ML VIAL 10ML to the Defense Logistics Agency (DLA) Troop Support Medical. The $46,236.16 contract has a firm fixed price pricing type and an ultimate completion date of August 15, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999 through December 2025, for delivering...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract, valued at $12,019.28, is for the procurement of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. The contract is a Firm Fixed Price Delivery Order, with a final completion date of February 27, 2025. Amerisourcebergen also holds a significant Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $96,154.24 firm fixed-price delivery order is for the provision of OCREVUS 300 MG/10 ML vials, a specialty medication. The contract has an ultimate completion date of February 14, 2025 and was awarded on January 24, 2025. This award is not designated as a set-aside contract. AmerisourceBergen holds a significant...